Andere talen Marksans Pharma Limited Bombay S.E.

Aandelen

MARKSANS

INE750C01026

Vertraagde tijd Bombay S.E. Andere beurzen 12:00:47 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
165,8 ^INR	-1,95%		-2,15%	+3,08%

14/02	Transcript : Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024
13/02	Marksans Pharma Limited rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA	18/04
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Marksans Pharma Arm Gets UK Regulator's Approval to Market Cyanocobalamin Tablets	06/11
Marksans Pharma Undergoes Successful Inspection from German Health Authorities	01/11
CARE Affirms A+ Rating on Marksans Pharma's Long-term Bank Financing; Outlook Stable	12-10-23
Marksans Pharma Gets US FDA Nod for Esomeprazole Magnesium Delayed-Release Capsules	03-10-23
Marksans Pharma Limited Announces US FDA Approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg	03-10-23
Marksans Pharma Limited Approves Payment of Dividend	28-08-23
Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director	28-08-23
Marksans Pharma Gets US FDA's Final Approval for Generic Cough Medicine	22-08-23
Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets	22-08-23
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11-08-23
Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23	08-08-23
Marksans Pharma's Goa Plant Gets Two Observations from US FDA	07-08-23
Marksans Pharma Gets US FDA Nod for Pain Relief Drug	12-07-23
Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg	12-07-23
Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023	30-05-23
Marksans Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30-05-23
Marksans Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Marksans Pharma Limited Bombay S.E.

Aandelen

MARKSANS

INE750C01026

Andere talen

Filters